Certified by Founder
Lodge
Asimov
start up
United States
- Boston, Massachusetts
- 09/01/2023
- Series B
- $200,000,000
Asimov builds tools to program living cells. By integrating mammalian synthetic biology, computer-aided design, and machine learning, our multi-disciplinary team is advancing the design and manufacture of biologics and gene therapies.
- Industry Biotechnology Research
- Website https://www.asimov.com/
- LinkedIn https://www.linkedin.com/company/asimov/
Iridius | $8,600,000 | (Apr 28, 2026)
SquareMind | $18,000,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Fathom Therapeutics | $47,000,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)
Zócalo Health | $15,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)